SCHEMBL14035668

SCHEMBL14035668

CCNc1ccc2c(cnn2C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM5 Q9NZQ8 1/20 0.59
CDC7 O00311 1/20 0.52
NOTUM Q6P988 1/20 0.48
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 1/20 0.46
GRM4 Q14833 1/20 0.46
MAOB P27338 3/20 0.46
MAOA P21397 2/20 0.46
ACHE P22303 1/20 0.46
SYK P43405 2/20 0.43
CTNNB1 P35222 1/20 0.43
TCF7 P36402 1/20 0.43
TGFBR1 P36897 2/20 0.42
VNN1 O95497 1/20 0.41
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13996634 0.88 CYP1A2 (0.47) TRPM5CDC7NOTUMCYP1A2GRM4
SCHEMBL13106720 0.83 TRPM5 (0.53) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL8311439 0.82 CDC7 (0.55) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL30279147 0.82 CDC7 (0.55) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL16406933 0.82 TRPM5 (0.56) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL13106705 0.82 TRPM5 (0.56) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL13993990 0.81 CDC7 (0.51) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL20369249 0.81 CDC7 (0.54) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL3274399 0.81 CDC7 (0.57) TRPM5CDC7NOTUMNPC1ALDH1A1
SCHEMBL13106733 0.80 TRPM5 (0.53) TRPM5CDC7NOTUMNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-3828174-A1 PYRIDAZINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-06-02 EP disclosed
EP-2464228-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 TRPM5 37/4885CDC7 3601/4885NOTUM 1736/4885
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 TRPM5 3235/4885CDC7 47/4885NOTUM 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.